Brandwood Biomedical and Capital K Consulting to become Brandwood-CKC
We are excited to announce the planned merger of Brandwood Biomedical and Capital K Consulting as of 1st July 2019 to form Brandwood-CKC.
Brandwood Biomedical, founded in 2000 is Australia’s leading provider of international regulatory, reimbursement and product development consultancy for medical devices and IVDs.
Officially launched in 2009, Capital K Consulting is a respected expert regulatory services provider for corporations with Australia & New Zealand prescription and OTC medicines.
Robert Stringer, Managing Director of Capital K Consulting explained: “This merger will bring together two leading expert technical consulting firms to offer comprehensive pre-launch services in an era of increasingly complex technologies which intersect and reinvent medicines, devices and diagnostics, hardware and software to produce innovative new life science products”.
“We have always taken a global view, with a deep engagement in the process of international harmonization of regulation. This merger is a natural progression towards a truly integrated service offering across all areas of therapeutics and diagnostics in global markets” said Arthur Brandwood, Founder and Principal Consultant of Brandwood Biomedical. The expanded business will support a client base of more than 100 leading providers of therapeutics, ranging from start-ups to top-10 multinationals.
Grant Bennett, Inaugural CEO of Brandwood-CKC said: “This merger of two very well-respected firms in the industry brings technical strength and diversity, coupled with an integrated commercial focus, making Brandwood-CKC the premier regulatory partner for any local or international healthcare product corporation.”
Brandwood-CKC will be headquartered in St Leonards, Sydney and has international offices in Los Angeles, Wellington, Beijing, Taipei, Hong Kong and Hyderabad.
Brandwood-CKC will offer regulatory, reimbursement, quality systems, technical and regulatory appeal services addressing Australia, New Zealand and the broader Asia-Pacific, North America and European markets.